A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel(The Netherlands Cancer Institute), Jan H.M. Schellens(Utrecht University), Samer El Bawab(Merck KGaA, Darmstadt (Germany)), Patrick Schöffski(KU Leuven), Iván Díaz-Padilla(Center for Global Development), Karin Berghoff(Merck KGaA, Darmstadt (Germany)), Lars Damstrup(Merck KGaA, Darmstadt (Germany)), Barbara Sarholz(Merck KGaA, Darmstadt (Germany)), Mirjam Kuipers(Merck KGaA, Darmstadt (Germany)), Morten Mau‐Sørensen(Rigshospitalet), Henk M.W. Verheul(Erasmus MC Cancer Institute), Dorte Nielsen(Herlev Hospital), Maja J.A. de Jonge(Erasmus MC Cancer Institute), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell)
British Journal of Cancer
November 24, 2020
10.1038/s41416-020-01151-6
Cited by 127

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k